Regulus Therapeutics, Inc
Regulus Therapeutics is dedicated to developing innovative oligonucleotide therapeutics targeting microRNA for the benefit of patients with genetically based orphan diseases, especially kidney diseases like ADPKD. Their mission is to improve patients' lives through novel therapies based on their proprietary technology and strategic IP licensing from Alnylam and Ionis.
Industries
biotechnology
genetics
health-care
therapeutics
Nr. of Employees
medium (51-250)
Regulus Therapeutics, Inc
4224 Campus Point Court, Suite 210, San Diego, CA 92121
Patents
Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
US-12005120-B2
View Details
Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
US-12005120-B2
View DetailsProducts
Anti‑miR‑17 oligonucleotide candidates for ADPKD
Preclinical and development-stage oligonucleotide candidates designed to inhibit miR‑17 for treatment of Autosomal Dominant Polycystic Kidney Disease.
Anti‑miR‑17 oligonucleotide candidates for ADPKD
Preclinical and development-stage oligonucleotide candidates designed to inhibit miR‑17 for treatment of Autosomal Dominant Polycystic Kidney Disease.
Services
Partnerships and in‑licensing arrangements to co-develop oligonucleotide programs and leverage company expertise and IP in microRNA therapeutics.
Partnerships and in‑licensing arrangements to co-develop oligonucleotide programs and leverage company expertise and IP in microRNA therapeutics.
Expertise Areas
- MicroRNA therapeutics
- Oligonucleotide chemistry and CMC
- Translational research and preclinical development
- Drug metabolism and pharmacokinetics (DMPK)
Key Technologies
- MicroRNA-targeting oligonucleotides
- Anti‑microRNA (anti‑miR) therapeutic approaches
- Oligonucleotide conjugation strategies
- Preclinical in vivo disease models